Relmada Therapeutics, Inc. RLMD Other Income - Net
Other Income - Net at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s other income - net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s other income - net?
- Relmada Therapeutics, Inc. (RLMD) reported other income - net of $409.8K in Q1 2026.
- How has Relmada Therapeutics, Inc.'s other income - net changed year-over-year?
- Relmada Therapeutics, Inc.'s other income - net decreased by 37.8% year-over-year, from $658.97K to $409.8K.
- What is the long-term trend for Relmada Therapeutics, Inc.'s other income - net?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s other income - net has grown at a 144.1% compound annual growth rate (CAGR), from -$48.32K to $1.72M.
- What does other income - net mean?
- Includes financial impacts from activities outside the company's primary business operations, such as interest expense, foreign exchange gains or losses, and other miscellaneous income. This metric helps isolate the impact of non-core financial events on the bottom line.